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Eight of the top 50 substances on the 1997
Agency for Toxic Substances and Disease
Registry (ATSDR) priority list (ATSDR
2001) are toxic metals, including arsenic,
chromium, cadmium, and nickel. Exposure
to these metals is associated with a variety of
adverse health effects; however, the mecha-
nisms that lead to the development of these
diseases and the subcellular pathways modi-
fied in response to metal exposures are not
well understood. Metal-specific biomarkers
of exposure, effect, or susceptibility are
needed for risk assessment and epidemio-
logic studies exploring the important health
effects of exposure to these metals.
Arsenic exposure can occur through
ingestion of contaminated drinking water,
particularly in regions with geologic
sources of arsenic, including Bangladesh,
Taiwan, and Chile and parts of the United
States such as New Hampshire, Michigan,
Nevada, and California (Gebel 2000, 2001).
Arsenic can also enter the body via inhala-
tion, which is particularly important for
certain occupational exposures (Abernathy
et al. 1999; ATSDR 1999a; IARC 1980).
Dermal exposure does not appear to lead to
significant systemic uptake, although local
dermal exposure such as with Fowler’s
solution or arsenical pesticides has been
associated with skin effects at the site of
application (Baudouin et al. 2002). Chronic
arsenic exposure has been associated with
increased incidence of vascular and cardio-
vascular disease, diabetes, hyperkeratosis,
and cancers of the skin, lung, liver, bladder,
kidney, and colon (ATSDR 1999a; Byrd
et al. 1996; Leonard and Lauwerys 1980).
The primary route of toxicologic con-
cern for exposure to both nickel and
chromium is inhalation, principally in
occupational settings, although environ-
mental exposures can also occur as a result
of anthropogenic sources (IARC 1991;
Leikauf 2002; Williams and Sandler 2001).
It has been estimated that 1.5 million work-
ers are exposed to nickel occupationally in
the United States (IARC 1991). Particulate
nickel is emitted into the atmosphere dur-
ing oil and coal combustion, metal refining,
nickel-alloy manufacturing and grinding,
battery manufacturing, municipal incinera-
tion, electroplating, and stainless steel man-
ufacturing, as well as from cigarette smoke
and motor vehicle emissions, resulting
in environmental inhalation exposure
(Barceloux 1999; Laden et al. 2000;
NiPERA 1999). Dermal exposure can
occur through skin contact with soil, water,
or metals, including stainless steel or coins
containing nickel (ATSDR 1999b) and can
result in allergic reactions. Occupational
exposure to nickel via inhalation is associ-
ated with respiratory distress and lung and
nasal cancer (ATSDR 1999b; Denkhaus
and Salnikow 2002; Leikauf 2002). 
Chromium(VI) enters the air princi-
pally as a result of coal and oil combustion,
steel production, stainless steel welding, and
chemical manufacturing (ATSDR 1998;
Barnhart 1997; IARC 1991). Chromium
exposure can also occur from cigarette
smoke. Discharge from electroplating,
leather tanning, textiles, and dye and
pigment manufacturing can contaminate
water sources. Occupational exposure to
chromium(VI) through inhalation causes
respiratory tract problems and lung cancer,
whereas dermal contact can lead to allergic
contact dermatitis and skin ulceration
(Alcedo and Wetterhahn 1990; ATSDR
1998; Dayan and Paine 2001). 
Cadmium inhalation can occur occupa-
tionally during battery manufacturing,
metal soldering, or welding, as well as envi-
ronmentally from burning fossil fuels,
municipal waste, or cigarettes, and is associ-
ated with respiratory damage and cancer.
Exposure can also occur through consump-
tion of food or water containing cadmium,
leading to gastrointestinal problems and
kidney and bone disease, as well as
increased body burdens of cadmium, which
has a half-life of greater than 20 years in
humans (ATSDR 2002; Beyersmann and
Hechtenberg 1997; Jarup et al. 1998). 
Identification of genes whose expres-
sion is specifically modified by toxic metal
exposure would provide a better under-
standing of their mechanisms of action and
allow development of sensitive and specific
biomarkers of both exposure and suscepti-
bility for use in both mechanistic labora-
tory and epidemiology studies. In the
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Examining global effects of toxic metals on gene expression can be useful for elucidating patterns
of biological response, discovering underlying mechanisms of toxicity, and identifying candidate
metal-specific genetic markers of exposure and response. Using a 1,200 gene nylon array, we exam-
ined changes in gene expression following low-dose, acute exposures of cadmium, chromium,
arsenic, nickel, or mitomycin C (MMC) in BEAS-2B human bronchial epithelial cells. Total RNA
was isolated from cells exposed to 3 µM Cd(II) (as cadmium chloride), 10 µM Cr(VI) (as sodium
dichromate), 3 µg/cm2 Ni(II) (as nickel subsulfide), 5 µM or 50 µM As(III) (as sodium arsenite),
or 1 µM MMC for 4 hr. Expression changes were verified at the protein level for several genes.
Only a small subset of genes was differentially expressed in response to each agent: Cd, Cr, Ni, As
(5 µM), As (50 µM), and MMC each differentially altered the expression of 25, 44, 31, 110, 65,
and 16 individual genes, respectively. Few genes were commonly expressed among the various
treatments. Only one gene was altered in response to all four metals (hsp90), and no gene over-
lapped among all five treatments. We also compared low-dose (5 µM, noncytotoxic) and high-dose
(50 µM, cytotoxic) arsenic treatments, which surprisingly, affected expression of almost completely
nonoverlapping subsets of genes, suggesting a threshold switch from a survival-based biological
response at low doses to a death response at high doses. Key words: arsenic, cadmium, chromium,
DNA microarray, hypoxia inducible factor-1α, kinase, mitomycin C, nickel, toxicogenomics,
toxicoproteomics. Environ Health Perspect 111:825–838 (2003). doi:10.1289/txg.6249 available
via http://dx.doi.org/ [Online 7 May 2003]
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current work we used cDNA microarrays
to compare the effects of the toxic metals
arsenic, cadmium, chromium, and nickel
on expression of 1,200 human genes in
human bronchial BEAS-2B cells, as lung is
a target for effects of all four of these met-
als. We also confirmed the expression of
certain relevant genes at the protein level in
both epithelial and vascular smooth muscle
cell models.
Methods
Cell treatment and preparation. Human
bronchial epithelial cells (BEAS-2B;
ATCC, Rockville, MD) were grown to
postconfluence in 75-cm2 flasks (Corning
Costar, Corning, NY) on a matrix of 0.01
mg/mL human fibronectin (Collaborative
Biomedical Products, Bedford, MA),
0.03 mg/mL Vitrogen 100 (Collagen
Biomaterials, Palo Alto, CA), and 0.01
mg/mL bovine serum albumin (Sigma
Chemical Co., St. Louis, MO). The cul-
tures were maintained in LHC-9 medium
(Biofluids Inc., Rockville, MD) at 37ºC
under an atmosphere of 5% CO2/95% air,
and medium was changed 24 hr before
treatment.
Primary cultures of porcine smooth
muscle cells (pSMC) were grown from
medial explants of porcine aortas, using
established methods (Ross 1971). Briefly,
segments of thoracic aorta were cleaned of
outer adventitia, opened longitudinally,
and scraped to remove endothelial cells.
Segments of the remaining intima and
media were cut into 1-mm squares and
allowed to adhere to scored plastic dishes.
The squares were then cultured with
complete Dulbecco’s modified Eagle’s
medium (DMEM; Cellgro MediaTech
Inc., Herndon, VA) containing 1 mmol/L
glucose, 10% fetal bovine serum, and 1%
penicillin/streptomycin under an atmos-
phere of 10% CO2/90% air. The explants
were removed once cells began to grow
out. The cells were harvested in trypsin/
EDTA and replated for continued sub-
culturing or characterization by immuno-
histochemistry. All cultures stained greater
than 99% positive for α-actin. The cells
used in these experiments were from
passage 3 or 4.
For both cell types, treatments were cho-
sen that did not cause overt signs of toxicity
or changes in cell survival or replication as
measured by long-term colony-forming
assays. The exception was the 50-µM arsenic
treatment used for dose–response compar-
isons. In all other cases, the doses of metal
are relevant to those to which humans could
be exposed. For example, levels of nickel
found in the lungs of autopsied U.S. sub-
jects with no known occupational exposure
to nickel range between 1.8 and 2.1 mg
Ni/cm2 of lung surface area (Edelman and
Roggli 1989). Nickel refinery workers had
much higher levels of nickel in the lung
(mean 15 mg Ni/cm2) (IARC 1991). 
cDNA array analysis. One confluent
flask of > 107 cells BEAS-2B cells per treat-
ment group of control cells or cells exposed
to 5 or 50 µM sodium arsenite, 3 µM cad-
mium chloride, 10 µM sodium dichromate
(Aldrich, St. Louis, MO), 3 µg/cm2 of cell
culture flask nickel subsulfide (Sigma), or
1 µM mitomycin C (MMC) for 4 hr was
washed and scraped in ice-cold phosphate-
buffered saline. Cells were then cen-
trifuged, and the cell pellet was snap frozen
in liquid nitrogen. The expression of 1,200
genes was assessed by cDNA microarray
analysis using Clontech nylon membrane-
based Human Broad Coverage 1.2 I arrays
(Clontech Laboratories Inc., Palo Alto,
CA). Densitometry was performed on the
hybridized membranes using a phospho-
imager and the data were analyzed using
AtlasImage software (Clontech Laboratories).
The presence of nine housekeeping genes
per array allowed us to discard housekeep-
ing genes that were induced or repressed by
a particular treatment (typically one to two
of nine included on the array). The expres-
sion of each gene was normalized to the
average of the remaining housekeeping
genes. The housekeeping genes included on
the array were ubiquitin, phospholipase A2,
hypoxanthine–guanine, phosphoribosyl-
transferase (HPRT), liver glyceraldehyde
3-phosphate dehydrogenase (GAPDH),
brain-specific tubulin alpha 1 subunit
(TUBA1), HLA class I histocompatibility
antigen C-4 alpha subunit (HLAC), cyto-
plasmic beta-actin (ACTB), 23-kDa highly
basic protein, 60S ribosomal protein L13A
(RPL13A), and 40S ribosomal protein S9.
The normalized ratios (treated divided
by control) and differences (treated minus
control) in gene expression between treated
and control samples were calculated for all
genes. Microarray analyses were repeated
using n = 7 independent cultures for the
housekeeping genes as well as two untreated
independent cultures for all 1,200 genes,
and inter-array variability was estimated to
be < 22%. Within a single array, the vari-
ability of housekeeping gene expression was
estimated to be between 8.4 and 20.9%.
The housekeeping genes were used to
calculate thresholds for each treatment.
Thresholds were determined using fold
changes 2 standard deviations outside of the
average housekeeping gene value. The fol-
lowing threshold values were assigned on the
basis of the underlying distribution of the
data: 5 µM arsenic: ratio 1.69, difference 4;
50 µM arsenic: ratio 2.0, difference 13;
chromium, cadmium, nickel, and MMC:
ratio 1.49, difference 4. In addition to set-
ting a threshold for the ratios, the difference
between the treated samples and the con-
trols was used to examine genes with low
expression levels in which a fold change
would be less reliable (e.g., 400/200 units
compared with 4/2 units).
Immunoblot. The effects of arsenic expo-
sure on hypoxia inducible factor-1α (HIF-
1α) or β-actin protein levels (used as a
loading control) were determined by
Western blotting using a polyclonal antibody
to HIF-1α (Transduction Laboratories,
Lexington, KY) or a monoclonal antibody to
β-actin (Sigma). Immunoblotting was per-
formed as described previously (Andrew
et al. 2001; Barchowsky et al. 1997). 
Kinase expression assay. For the kinase
expression assay, the medium of 1-day
postconfluent BEAS-2B cells was changed
12–18 hr prior to addition of 5 µM potas-
sium dichromate (Aldrich) and the cells
were treated for a time course of 1, 4, and
24 hr. pSMC were grown to 80–90% con-
fluence in 75-cm2 flasks (Corning Costar),
and the medium was changed to a serum-
free DMEM containing 1 mg/mL bovine
serum albumin 20 hr prior to the addition
of sodium arsenite. Cells were treated
with 2.5 µM As for 1, 4, and 12 hr. A
dose–response experiment using 1, 2.5,
and 10 µM As was performed at 24 hr.
Following treatment, cells were rinsed with
Tris-buffered saline containing protease
inhibitors, as described previously. The
cells were then prepared as described
(Kinexus Bioinformatics Corp. 2001).
Briefly, the cells were lysed in 20 mM
3-(N-morpholino)propanesulfonic acid,
pH 7.0; 2 mM EGTA; 5 mM EDTA;
30 mM sodium fluoride; 40 mM β-glycero-
phosphate, pH 7.2; 10 mM sodium pyro-
phosphate; 2 mM sodium orthovanadate;
and 0.5 % Nonidet P-40, supplemented
with protease inhibitors. The cell lysates
were sonicated twice for 15 sec and cen-
trifuged for 2 hr at 19,000 rpm at 4˚C.
A protein assay was performed on the
supernatant, and a cell lysate mixture was
adjusted to a concentration of 1 µg/µL
using a 4 × sample buffer (50% glycerol;
125 mM Tris–HCl, pH 6.8; 4% sodium
dodecyl sulfate; 0.08% bromophenol
blue; 5% β-mercaptoethanol). Samples
were heated at 100˚C for 4 min. The sam-
ples were analyzed via the Kinetworks’
Protein Kinase Screen 1.0, a multiplexed
western blot service provided by Kinexus
Bioinformatics Corp. (Vancouver, British
Columbia, Canada). Kinexus loaded equal
amounts of protein, quantified the blots
by densitometry, and analyzed them using
their proprietary software.
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Results
BEAS-2B human lung bronchial epithelial
cells were treated for 4 hr either with arsenic
(as sodium arsenite, 5 or 50 µM), cadmium
(as cadmium chloride, 3 µM), chromium (as
sodium dichromate, 10 µM), nickel (as
nickel subsulfide, 3 µg/cm2), or the geno-
toxic cancer chemotherapy drug MMC
(1 µM). cDNA array analysis with 1,200
human genes (Clontech 1.2; Clontech) was
performed with each treatment. The
selected threshold fold change for each treat-
ment was outside the 1.49- to 2.0-fold range
in expression seen in the housekeeping genes
(average plus 2 standard deviations).
The genes listed in Figure 1 showed
increased or decreased expression follow-
ing each treatment (see “Materials and
Methods” for details). This Boolean
schematic representation lists the genes
uniquely changed by each exposure within
the appropriate shape, with overlapping
regions (or underlining for arsenic) indicat-
ing genes that were modified by more than
one treatment. To summarize the data,
low-dose cadmium altered the expression
of 25 genes; chromium, 44; nickel, 31;
5 µM arsenic, 110 (Figure 2); 50 µM
arsenic, 65; and MMC, 16 genes.
As shown in Figure 1, although there
was some overlap, overall each treatment
modified expression of a largely unique set
of genes. Only heat-shock protein 90A
(HSP 90A) expression was modified by
treatment with all four of the metals tested,
and no gene’s expression was modified by
all five treatments. Several genes were dif-
ferentially regulated in response to three
metals: cadmium, chromium, and nickel.
Specifically, these three metals induced
expression of erythrocyte glucose trans-
porter 1 (GLUT1) and decreased transcrip-
tional activator (DB1), collagen type
4 (COL4A2), glutathione peroxidase
(GSHPX1), hepatoma-derived growth fac-
tor (HDGF), and cytochrome P450 1B1
(CYP1B1) (Figure 1, overlapping region).
Interestingly, when two or more exposures
affected expression of the same gene, the
expression was usually altered in the same
direction, that is, increased or decreased,
with each exposure. The only exception
was that treatment with the organic DNA-
damaging agent MMC induced expres-
sion of early growth response protein 1
(hEGR1), whereas chromium, arsenic, and
nickel all suppressed expression of this gene
(Figure 1, black font).
To explore the effects of dose on the
gene expression profile, we exposed cells for
4 hr to two different doses of arsenic:
5 µM, which caused little or no cytotoxic-
ity, or 50 µM, which was highly cytotoxic
as determined by a colony-forming assay.
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Underlining indicates expression also
















































































Figure 1. Gene expression profiles for cells treated with cadmium, chromium, nickel, or MMC. Relative
expression of 1,200 genes was assessed in human bronchial BEAS-2B cells exposed for 4 hr to cadmium
(10 µM Cd2+ as cadmium chloride), chromium(VI) (10 µM Cr(VI) as sodium dichromate), nickel (3 µg/cm2
Ni2+ as nickel subsulfide), and mitomycin C (1.0 µM MMC) using cDNA microarray analysis. Genes with
expression changes above a statistically derived threshold for an exposure (minimum 1.5-fold) are listed
within each designated shape using the abbreviations defined in Table 1. Font color indicates an increase
(red) or decrease (blue) in expression relative to control. Black font indicates a gene whose expression
was induced by one treatment but suppressed by another. Genes with modified expression following
exposure to more than one metal are found in the relevant overlapping areas. Genes modified by arsenic




































































































































































Figure 2. Gene expression profiles for cells treated with 5 or 50 µM arsenic. Ubiq., ubiquitin. Relative
expression of 1,200 genes was assessed in human bronchial BEAS-2B cells exposed for 4 hr to arsenic
[5 or 50 µM As(III) as sodium arsenite] as described in Figure 1. Font color indicates an increase (red) or
decrease (blue) in expression relative to control. The overlapping region contains a list of genes affected
by both 5 and 50 µM arsenic.
Of the 1,200 genes examined at both
doses, only 16 of 158 affected genes were
altered at both doses (Figure 2, overlapping
region). All genes altered by 50 µM arsenic
were increased in expression (red font) with
the exception of monocyte chemotactic
protein 1 precursor (MCP1) (blue font). In
contrast, 5 µM arsenic increased (red font)
or decreased (blue font) expression of genes
in similar numbers. Interestingly, more
total genes were affected by the lower dose
than by the higher cytotoxic dose. As
might be expected, at the higher dose,
stress response and apoptotic genes pre-
dominated. Interestingly, most of these
genes were unaffected at the lower dose.
Western immunoblot and kinase
expression assays were performed for certain
genes to determine whether the altered gene
expression seen in the microarray assays was
paralleled by a change in protein expression.
Immunoblots (Figure 3) demonstrated
increases in protein levels of the transcrip-
tion factor HIF-1α, following exposure to
arsenic for 4, 8, or 24 hr, which are consis-
tent with the increased HIF-1α mRNA
levels observed after 5-µM arsenic exposure
(Figure 2). This level of arsenic exposure
did not affect β-actin expression, which was
used as a loading control.
Assays for kinase protein expression
changes were performed on cells exposed to
arsenic or chromium over a range of doses
and time points in two separate cell types.
The ratio of mRNA levels in exposed versus
control cells (Figure 4) was compared with
the ratio of protein levels observed in the
kinase expression assay for each kinase
(Figure 4). ERK3 gene and protein levels
were increased at most arsenic doses and
time points tested (Figure 4A), whereas
RSK1, PKACα, and PKBα/akt1 all showed
consistent decreases in expression following
arsenic exposure in both assays (Figure
4B–D). Chromium exposure also decreased
mRNA and protein levels of PKBα/akt1
(Figure 4E). Thus, for the genes and gene
products examined, changes in mRNA
expression were similar to changes in
protein expression.
Discussion
Chronic exposure to the toxic metals
arsenic, chromium, cadmium, and nickel
has been associated with a wide variety of
adverse health effects (ATSDR 1998,
1999a,1999b, 2002). Previous studies of
individual genes have demonstrated that
these metals can each substantially alter
gene expression in various cell and whole
animal systems (Andrew and Barchowsky
2000; Hamilton and Wetterhahn 1989;
Hamilton et al. 1998; Ihnat et al. 1997;
McCaffrey et al. 1994). The development
of gene array technology has provided a
means for examination of alterations in
gene expression on a more global level. The
current study describes profiles of early
changes in gene and protein expression that
Toxicogenomics | Andrew et al.
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Figure 3. Effects of arsenic on HIF-1α protein
expression. (A) Confluent BEAS-2B cells were
exposed to 2.5 µM arsenic for 4, 8, or 24 hr. Cells
were harvested for total protein and Western
blots were performed as described in “Materials
and Methods,” using antibodies to HIF-1α or the
loading control β-actin. (B) The band density ratio
of HIF-1α to β-actin density of bands shown in A.
Data represent protein collected from indepen-
dent experiments. Values are means SD; n = 3. 8-
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PKBα/akt1
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Figure 4. Comparison of gene expression and protein kinase expression profiles for cells treated with
chromium and arsenic. Changes in the kinases (A) ERK3, (B) RSK1, (C) PKCα, and (D) PKBα in response to
arsenic exposure were measured at both the gene level by cDNA array analysis and at the protein level
by a kinase assay as described in “Materials and Methods.” Data under the heading “Array” represent
the normalized ratio of gene expression for arsenic-exposed cells compared with that of control, whereas
data under the heading “Kinase expression assay” represent the ratio of protein levels for arsenic-
exposed smooth muscle cells compared with that of control. (E) This graph shows the ratio of changes in
PKBα gene and protein expression after chromium treatment, as described above for arsenic. Treatment
time is indicated on the graph below each bar, and bar shading designates the dose of arsenic or
chromium, as shown in the legend.
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Table 1. Relative expression of genes for cells treated with arsenic, chromium, cadmium, nickel, or MMC.a
Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
3pK MAPKAP kinase (3pK) 2.00 U09578
5-HT-3 5-Hydroxytryptamine 3 receptor 2.00
precursor (5-HT-3); serotonin-gated 
ion channel receptor D49394
A1ATR Alpha-1-antitrypsin precursor; 1.54 1.65 X02920
alpha-1 protease inhibitor; 
alpha-1-antiproteinase
ABLL Tyrosine-protein kinase ABL2; 2.44 M35296
tyrosine kinase ARG (ABLL)
ADA2 ADA2-like protein 2.33 AF069732
AIM1 Aurora- & IPL1-like midbody-associated 2.00 AF008552
protein kinase 1 (AIM1); ARK2
ALG-2 ALG-2 calcium-binding protein 2.40 AF035606
AP-1 Proto-oncogene c-jun; transcription 15.42 J04111
factor AP-1
APE1 DNA-(apurinic or apyrimidinic site) 2.07 X59764;
lyase; AP endonuclease 1; APEX X66133
nuclease (APEN; APE1); REF-1 protein
AREB6 Transcription factor AREB6 5.00 D15050
ARHB Transforming protein rhoB; ARHB; ARH6 1.83 X06820
ATF-3 Cyclic-AMP-dependent transcription 6.33 L19871
factor ATF-3 (activating factor 3)
sodium/potassium-transporting ATPase
ATPB3 Beta 3 subunit (ATPB3); sodium/ 1.83 U51478
potassium-dependent ATPase
B94 B94 protein 2.00 3.50 2.33 M92357
BAG-1 BCL-2 binding athanogene-1 (BAG-1); 1.70 S83171;
glucocorticoid receptor-associated Z35491
protein RAP46
BAX Apoptosis regulator bax 2.11 L22474
bcl-6 B-cell lymphoma 6 protein (bcl-6); zinc 2.14 U00115
finger protein 51 (ZNF51); LAZ-3 protein
BCL-X Apoptosis regulator bcl-x 1.89 Z23115; 
L20121;
L20122
BDNF Brain-derived neurotrophic factor (BDNF) 6.33 M61176
BMP4 Bone morphogenetic protein 4 (BMP4) + 2.00 3.00 3.00 D30751 +
bone morphogenetic protein 2B (BMP2B) M22490
BRCA1 BRCA1-associated ring domain protein 2.17 X82200
BRCA2 Breast cancer type 2 susceptibility 2.17 U43746
protein (BRCA2)
BSP1 Transforming growth factor-beta 3.50 2.44 U57456
signaling protein 1 (BSP1); mothers 
against dpp homolog (MAD); MADR1; 
MSMAD1
BTEB2 Basic transcription element-binding 2.26 2.59 D14520
protein 2 (BTEB2); GC-box binding 
protein 2
BTF2p44 Basic transcription factor 2 44-kDa 1.90 Z30094
subunit (BTF2p44)
CANP Calpain 2 large (catalytic) subunit; 1.82 M23254
M-type calcium-activated neutral
proteinase (CANP)
CAP2 Cytoplasmic antiproteinase 2 (CAP2); 2.00 L40377
protease inhibitor 8
CASP2 Caspase-2 precursor (CASP2); ICH-1L 4.00 U13021 +
protease + ICH-1S protease U13022
(Continued on next page)
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Table 1—Continued.
Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
CASP4 Caspase-4 precursor (CASP4); ICH-2 1.53 U28014 +
protease; TX protease; ICE(REL)-II + U28015
caspase-5 precursor (CASP5); ICH-3 
protease; TY protease; ICE(REL)-III
CBF-B CCAAT-binding transcription factor 1.50 M59079
subunit B (CBF-B); NF-Y protein subunit
A (NF-YA); Hap2; CAAT-box DNA-binding 
protein subunit A
CCNB1 G2/mitotic-specific cyclin B1 (CCNB1) 1.51 M25753
CD40-L CD40 ligand (CD40-L); tumor necrosis 2.80 L07414
factor (TNF)-related activation protein 
(TRAP); T-cell antigen GP39
C-ets-2 C-ets-2 3.33 J04102
CI-B18 NADH-ubiquinone oxidoreductase B18 1.67 M33374
subunit; complex I-B18 (CI-B18); cell 
adhesion protein SQM1
CIP1 Cyclin-dependent kinase inhibitor 1 3.78 U09579; 
(CDKN1A); melanoma differentiation- L25610
associated protein 6 (MDA6); CDK- L29222
interacting protein 1 (CIP1); WAF1
CLK1 CDC-like kinase 1 (CLK1) 2.78 M74816
CLU Clusterin precursor (CLU); complement- 2.79
associated protein SP-40,40; complement 
cytolysis inhibitor (CLI); apolipoprotein 
J (APO-J); TRPM-2; sulfated glycoprotein 2
c-myc c-myc oncogene 3.49 3.42 1.95 V00568
COLα2 Procollagen alpha 2(IV) subunit precursor 2.00 1.75 1.75 X05562
Cortactin Cortactin; amplaxin; ems-1 oncogene 1.75 1.76 M98343
CRAF1 CD40 receptor-associated factor 1 (CRAF1) 5.00 U21092
CREB2 cAMP-dependent transcription factor 2.62 1.72 1.58 D90209
ATF-4; DNA-binding protein TAXREB67; 
cAMP-response element binding protein 
(CREB2)
CTNNA1 Alpha1 catenin (CTNNA1); cadherin- 1.76 D13866;
associated protein; alpha E-catenin D14705; 
L23805;
L22080
Cycin k Cyclin K 2.13 2.13 AF060515
CYP Cytochrome P450 reductase 3.00 S90469
CYP1B1 Dioxin-inducible cytochrome P450 3.50 3.50 2.33 U03688
1B1 (CYP1B1)
DAD1 Defender against cell death 1 (DAD1) 2.07 D15057
DAXX DAXX 2.50 AF015956
DB1 Putative transcription activator DB1 2.33 1.75 1.75 D28118
DBP DNA-binding protein TAXREB302; 2.27 D28468
albumin D box-binding protein (DBP)
DBP-A DNA-binding protein A 1.76 M24069
DFF45 DNA fragmentation factor 45 (DFF45) 3.00 U91985
DIF-2 IEX-1L anti-death protein; PRG-1; 3.09 2.60 1.80 AF039067;
DIF-2 AF071596
DPD DNA polymerase delta catalytic subunit 2.18 M80397
DPP-1 Dipeptidyl-peptidase I precursor (DPP-I); 1.83 X87212
cathepsin C; cathepsin J; dipeptidyl 
transferase
DRPLA Atrophin-1; dentatorubral-pallidoluysian 3.00 D31840
atrophy protein (DRPLA)
E16 E16 amino acid transporter 2.63 AF077866
E2F-3 E2F-3 2.17 Y10479
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Table 1—Continued.
Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
EAR2 v-erbA-related protein (EAR2) 2.08 X12794
EB1 EB1 protein 2.20 2.04 1.53 U24166
ECK Ephrin type-A receptor 2 precursor; 2.54 2.00 1.80 1.50 M59371;
epithelial cell kinase (ECK); tyrosine- M36395
protein kinase receptor ECK
EFNA4 Ephrin A4 precursor (EFNA4); EPH- 7.00 U14188
related receptor tyrosine kinase ligand 
4 (EPLG4); LERK4
EPH Ephrin type-A receptor 1 precursor; 2.88 M18391
tyrosine-protein kinase receptor eph
ERF1 TIS11B protein; EGF response factor 1 3.37 2.00 2.00 X79067
(ERF1)
ERK3 Extracellular signal-regulated kinase 3 1.70 3.92 X80692
(ERK3); MAP kinase 3 (MAPK3;
p97-MAPK); PRKM5
ETR101 Transcription factor ETR101 4.03 3.00 M62831
ETS-1 Erythroblastosis virus oncogene homolog 3.21 J04101
1 (ETS-1); p54
ETV6 ets-related protein tel; ets translocation 2.27 U11732
variant 6 (ETV6)
FAST fas-activated serine/threonine (FAST) 2.75 X86779
kinase
FGFR1 N-sam; fibroblast growth factor receptor1 3.00 3.00 X66945;
precursor (FGFR1); basic fibroblast growth M34641;
factor receptor precursor (bFGFR); fms-like M34186; 
tyrosine kinase-2 (FLT2) + heparin-binding M37722 +
growth factor receptor (HBGF-R-alpha-A1) + M63887 + 
HBGF-R-alpha-A2 + HBGF-R-alpha-A3 M63888 + 
M63889
FRA1 fos-related antigen (FRA1) 8.59 1.80 X16707
Fte-1 fte-1; yeast mitochondrial protein import 1.50 1.52 1.55 M77234
homolog; 40S ribosomal protein S3A
(RPS3A )
FX Thymosin beta 4; FX 2.21 1.74 M17733
GABP-α GA-binding protein alpha subunit (GABP- 2.33 D13316
alpha); transcription factor E4TF1-47; 
nuclear respiratory factor-2 alpha subunit
GADD153 Growth arrest and DNA-damage-inducible 10.35 S40706;
protein 153 (GADD153); DNA-damage- S62138
inducible transcript 3 (DDIT3); C/EBP 
homologous protein (CHOP) 
GADD45 Growth arrest and DNA-damage-inducible 2.60 13.88 M60974
protein (GADD45); DNA-damage-inducible 
transcript 1 (DDIT1)
GADD45β Growth arrest and DNA-damage-inducible 3.23 AF078077
protein 45 beta (GADD45 beta)
GALNR1 Galanin receptor type 1 (GALNR1; GALR1) 2.78 L34339
GAP GAP-associated protein 2.00 U17032
GLUT1 Erythrocyte glucose transporter 1 (GLUT1) 1.86 1.64 1.93 K03195
GNBP Guanine nucleotide-binding protein 2.50 M36429
G-i/G-s/G-t beta subunit 2; transducin 
beta 2 subunit 2
GRRF1 Glucocorticoid receptor repression factor 1 2.00 M73077
GSHPX1 Glutathione peroxidase (GSHPX1; GPX1) 2.00 1.68 1.62 Y00483;
M21304
GSR Glutathione reductase (GRase; GSR; GR) 1.60 X15722
H2TF1 Nuclear factor NF-kappa-B p100 subunit; 1.71 X61498
nuclear factor NF-kappa-B p52 subunit; 
H2TF1; oncogene lyt-10
(Continued on next page)
Toxicogenomics | Andrew et al.
832 VOLUME 111 | NUMBER 6 | May 2003 • Environmental Health Perspectives
Table 1—Continued.
Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
HATB2 Histone acetyltransferase B subunit 2; 1.80 1.80 U35143
retinoblastoma-binding protein p46; 
retinoblastoma-binding protein 7
HBEGF Heparin-binding EGF-like growth factor 16.29 M60278
(HBEGF); diphtheria toxin receptor (DTR)
HDGF Hepatoma-derived growth factor (HDGF) 1.67 1.55 1.55 D16431
hEGR1 Early growth response protein 1 (hEGR1); 2.36 13.00 2.17 1.62 X52541; 
transcription factor ETR103; KROX24; M62829
zinc finger protein 225; AT225
HEIR-1 Helix-loop-helix protein HLH 1R21; 2.41 X69111
DNA-binding protein inhibitor Id-3; HEIR-1
HIF1-α Hypoxia-inducible factor 1 alpha (HIF1 3.00 U22431
alpha); ARNT-interacting protein; member 
of PAS protein 1 (MOP1)
HLAC HLA class I histocompatibility antigen 1.52 M11886
C-4 alpha subunit (HLAC)
HO1 Heme oxygenase 1 (HO1); HSOXYGR 50.93 54.95 X06985
HOX-A5 Homeobox protein HOX-A5; HOX-1C 1.91 M26679
hSMN Survival of motor neuron (hSMN) 2.33 U18423
HSP-27 Heat-shock 27-kDa protein (HSP27); 4.28 X54079
stress-responsive protein 27 (SRP27); 
estrogen-regulated 24-kDa protein; HSPB1
HSP-40 Heat-shock protein 40 (HSP40) 13.86 1.50 D49547
HSP-60 Mitochondrial matrix protein P1 precursor; 3.13 2.00 M34664
p60 lymphocyte protein; chaperonin
homolog; HUCHA60; heat-shock protein 
60 (HSP-60); HSPD1
HSP-70 Heat-shock 70-kDa protein 6 (heat-shock 108.50 X51757;
70-kDa protein B) M11236
HSP70.1 70-kDa heat-shock protein 1 (HSP70.1; 5.48 45.83 M11717
HSPA1)
HSP-71 Heat-shock cognate 71-kDa protein 4.19 Y00371
HSP-90A Heat-shock 90-kDa protein A (HSP90A; 2.33 3.96 3.25 1.86 2.36 X07270
HSPCA); HSP86
HSR-70 Heat-shock–related 70-kDa protein 2 4.53 L26336
ICE-LAP3 Cysteine protease ICE-LAP3 2.33 U39613
Id-1H DNA-binding protein inhibitor ID-1; Id-1H 5.00 D13889
IGFBP3 Insulin-like growth factor-binding protein 2.00 M31159;
3 precursor (IGF-binding protein 3; M35878
IGFBP3; IBP3)
IL-10 Interleukin-10 precursor (IL-10); cytokine 1.54 M57627
synthesis inhibitory factor (CSIF)
IL-11 Interleukin-11 (IL-11); adipogenesis 13.33 M57765
inhibitory factor (AGIF)
IL-12B Interleukin-12 beta subunit precursor 2.50 6.00 M65290
(IL-12B); cytotoxic lymphocyte maturation 
factor 40-kDa subunit (CLMF p40); NK 
cell stimulatory factor subunit 2 (NKSF2)
IL-1R2 Interleukin-1 receptor type II precursor 2.40 X59770
(IL-1R2); IL-1R-beta
IL-2 Interleukin-2 precursor (IL-2); T-cell 1.90 A14844
growth factor (TCGF)
IL2RA Interleukin-2 receptor alpha subunit 1.74 X01057; 
precursor (IL-2 receptor alpha subunit; X01058;
IL2RA); p55; TAC antigen; CD25 X01402
IL-5RA Interleukin-5 receptor alpha subunit 2.66 M75914
precursor (IL-5R-alpha; IL5RA); CD125 
antigen
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Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
IL-6 Interleukin-6 precursor (IL-6); B-cell 3.11 2.78 2.45 X04602;
stimulatory factor 2 (BSF2); interferon M14584
beta-2 (IFNB2); hybridoma growth factor
IL-7 Interleukin-7 (IL-7) 1.73 J04156
IL-8 Interleukin-8 precursor (IL-8); monocyte- 2.95 4.46 Y00787
derived neutrophil chemotactic factor 
(MDNCF); T-cell chemotactic factor; 
neutrophil-activating protein 1 (NAP1);
lymphocyte-derived neutrophil-activating 
factor (LYNAP); protein 3-10C
ITGA4 Integrin alpha 4 precursor (ITGA4); VLA4; 2.54 L12002;
CD49D antigen X16983;
X15356
ITGB4 Integrin beta 4 (ITGB4); CD104 antigen 1.76 1.61 X53587;
,X52186;
X51841
JNKK c-jun N-terminal kinase kinase 1 (JNKK); 3.00 L36870
JNK activating kinase 1 (JNKK1); MAP 
kinase kinase 4 (MKK4)
JUN jun activation domain binding protein 2.43 U65928
jun-D jun-D 5.67 X56681
JUP,DP3 Junction plakoglobin (JUP); desmoplakin 2.33 1.60 M23410;
III (DP3) Z68228
LIF Leukemia inhibitory factor precursor (LIF); 2.15 7.63 X13967;
differentiation-stimulating factor (D factor); M63420
melanoma-derived LPL inhibitor (MLPLI); 
HILDA 
LIG1 DNA ligase I; polydeoxyribonucleotide 2.94 1.57 M36067
synthase (ATP) (DNL1) (LIG1)
LUCA2 LUCA2; lysosomal hyaluronidase 2 2.11 U09577
(HYAL2) ; PH-20 homolog
MAD MAD protein; MAX dimerizer 14.00 L06895
MAPKAPK-2 MAP kinase-activated protein kinase 1.50 1.50 U1277
2 (MAPKAP kinase 2; MAPKAPK-2) 9
MAPKK3 Dual specificity mitogen-activated protein 2.78 L36719
kinase kinase 3 (MAP kinase kinase 3; 
MAPKK 3; MKK3); ERK activator kinase 3;
MAPK/ERK kinase 3 (MEK3)
MCL-1 Induced myeloid leukemia cell 2.23 2.00 L08246
differentiation protein MCL-1
MCM2 MCM2 DNA replication licensing factor; 2.24 D21063
nuclear protein BM28; KIAA0030
MCM5 MCM5 DNA replication licensing factor; 1.72 X74795
CDC46 homolog
MCM7 MCM7 DNA replication licensing factor; 2.24 D55716
CDC47 homolog; p1.1-MCM3
MCP1 Monocyte chemotactic protein 1 precursor 2.21 7.00 2.33 M24545
(MCP1); monocyte chemotactic and 
activating factor (MCAF); monocyte 
secretory protein JE; monocyte 
chemoattractant protein 1; HC11; small 
inducible cytokine A2 (SCYA2)
MCT1 Monocarboxylate transporter 1 (MCT1) 3.50 L31801
MGMT 6-O-methylguanine-DNA methyltransferase 1.83 M29971
(MGMT); methylated-DNA-protein-cysteine 
methyltransferase
MIP2-α Macrophage inflammatory protein 2 alpha 2.03 2.11 X53799
(MIP2-alpha); growth-regulated protein 
beta (GRO-beta)
(Continued on next page)
Toxicogenomics | Andrew et al.
834 VOLUME 111 | NUMBER 6 | May 2003 • Environmental Health Perspectives
Table 1—Continued.
Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
MMP-14 Matrix metalloproteinase 14 precursor 1.67 D26512;
(MMP14); membrane-type matrix X83535
metalloproteinase 1 (MT-MMP1); MMP-X1
MRP macMARCKS; MARCKS-related protein 1.80 X70326
(MRP); MLP
NAK1 Early response protein NAK1; TR3 orphan receptor 7.83 L13740
NaKATPase Sodium/potassium-transporting ATPase 1.55 1.55 D00099
alpha 1 subunit (Na+/K+ ATPase)
NFKB3 NF-kappaB transcription factor p65 2.00 L19067
subunit; RELA; NFKB3
NF-X1 Transcriptional repressor NF-X1 3.00 U15306
NHE1 Sodium/hydrogen exchanger 1 (Na+/H+ 1.70 1.80 M81768
exchanger 1; NHE1); amiloride-sensitive 
Na+/H+ antiporter
NIP3 NIP3 (NIP3) 2.40 2.00 U15174
NMBR Neuromedin B receptor (NMBR); 1.76 M73482
neuromedin-B-preferring bombesin 
receptor
NOL1 Proliferating cell nucleolar antigen P120; 1.83 X55504
NOL1
NRGN Neurogranin (NRGN); RC3 1.75 Y09689
p15, PC4 Activated RNA polymerase II transcriptional 1.74 U12979
coactivator p15; PC4
p78 p78 putative serine/threonine-protein 2.36 M80359
kinase
PAR-1 Thrombin receptor (TR); F2R; PAR1 2.40 M62424
PBX1 Pre-B-cell leukemia transcription factor-1; 2.00 M86546
homeobox protein pbx1; Homeobox 
protein prl
PCNA Proliferating cyclic nuclear antigen 1.75 M15796;
(PCNA); cyclin J04718
PDGFA Platelet-derived growth factor A subunit 2.52 X06374
precursor (PDGFA; PDGF-1)
PI4K-α Phosphatidylinositol 4-kinase alpha 3.00 L36151
(PI4-kinase; PTDINS-4-kinase; PI4K-alpha)
PI4PK 68-kDa type I phosphatidylinositol-4- 2.86 X80907
phosphate 5-kinase alpha (PTDINS(4)P-5-
kinase); 1-phosphatidylinositol-4-phosphate 
kinase; diphosphoinositide kinase
PKACα cAMP-dependent protein kinase alpha- 2.33 X07767
catalytic subunit (PKA C-alpha)
PKB/akt rac-alpha serine/threonine kinase (rac- 1.74 1.53 M63167
PK-alpha); protein kinase B (PKB); c-akt; 
akt1
PLCG1 Phospholipase C gamma 1 (PLC-gamma 1; 2.11 M34667
PLCG1); 1-phosphatidylinositol 4,
5-bisphosphate phosphodiesterase 
gamma 1; PLC-II; PLC-148
PN-II Alzheimer’s disease amyloid A4 protein 1.74 1.86 Y00264
precursor; protease nexin-II (PN-II); APPI
POLG DNA polymerase gamma (POLG); 3.00 X98093
mitochondrial DNA polymerase catalytic 
subunit (MDP1)
PP-1A Serine/threonine protein phosphatase 1.65 M63960
PP1-alpha 1 catalytic subunit (PP-1A)
PRL-1 PTPCAAX1 nuclear tyrosine phosphatase 1.82 3.71 U48296
(PRL-1)
Prot.c8 Proteasome component C8; macropain 1.80 D00762
subunit C8; multicatalytic endopeptidase
complex subunit C8
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Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
PRP Major prion protein precursor (PRP); 2.05 2.54 1.62 1.90 M13667
PRP27-30; PRP33-35C; ASCR
PTMS Parathymosin 2.10 M24398
RAP-1B ras-Related protein RAP-1B; GTP-binding 2.25 X08004
protein SMG p21B
RFC Activator 1 140-kDa subunit (A1 140-kDa 2.00 L14922
subunit); replication factor C large subunit; 
DNA-binding protein PO-GA
RFC37 Activator 1 37-kDa subunit; replication 2.59 1.73 1.54 M87339
factor C 37-kDa subunit (RFC37); RFC4
RFC40 Activator 1 40-kDa subunit; replication 
factor C 40-kDa subunit (RFC40); RFC2 1.90 M87338
RHO-GDI rho GDP dissociation inihibitor 1 
(RHO-GDI 1); RHO-GDI alpha (GDIA1); 
ARHGDIA 1.81 1.67 X69550
RκB R kappa B DNA-binding protein 1.62 U08191
ROBO1 Roundabout 1 (ROBO1) 1.75 AF040990
RP-A Replication protein A 14-kDa subunit 1.90 1.70 L07493
(RP-A) (RF-A); replication factor A protein 3
RPL6 60S ribosomal protein L6 (RPL6); TAX- 2.10 X69391
responsive enhancer element binding 
protein 107 (TAXREB107); neoplasm-
related protein C140
RPS19 40S ribosomal protein S19 (RPS19) 1.95 M81757
RSK1 Ribosomal protein S6 kinase II alpha 1 1.72 1.75 L07597
(S6KII-alpha 1); ribosomal S6 kinase 1
(RSK1)
SAP2 ets Domain protein elk-3; NET; SRF 1.91 Z36715
accessory protein 2 (SAP2)
SATT Neutral amino acid transporter A 2.08 L14595
(SATT); alanine/serine/cysteine/threonine 
transporter (ASCT1)
Shb shb proto-oncogene 3.01 1.62 X75342
SMAD4 Mothers against dpp homolog 4 (SMAD4); 3.50 U44378
MADR4; pancreatic carcinoma gene 
4 (DPC4)
SNK Serum-inducible kinase (SNK) 2.75 AF059617
Stratifin 14-3-3 Protein sigma; stratifin; epithelial 1.88 AF029082
cell marker protein 1
Synapsin Synapsin IIIA 1.90 AF046873
TAFAP-2 Transcription factor AP-2 (TFAP2; AP2TF) 1.80 M36711
TIF1 Transcription intermediary factor 1 (TIF1) 1.80 AF009353
tnk1 Tyrosine kinase tnk1 1.78 1.78 U43408
TOB Transducer of ERBB2 (TOB) 2.31 D38305
TOP2A DNA topoisomerase II alpha (TOP2A) 3.50 J04088
TR Thioredoxin reductase 3.29 X91247
TRRAP TRRAP protein 2.00 1.75 AF076974
TSC2 Tuberin; tuberous sclerosis 2 protein (TSC2) 2.22 X75621
TST Thiosulfate sulfurtransferase; rhodanese 5.00 D87292
TTR Transthyretin precursor (TTR); prealbumin; 1.89 K02091
TBPA
TYK2 tyk2 non-receptor protein tyrosine kinase 1.86 X54637
Ubiquitin Ubiquitin 2.03 7.94 2.16 1.82 M26880
UNG1 Uracil-DNA glycosylase precursor (UNG1) 5.57 X15653
UPAR Urokinase-type plasminogen activator 1.62 U08839; 
receptor GPI-anchored form precursor M83246;
(U-PAR); monocyte activation antigen MO3; X51675
CD87 antigen
(Continued on next page)
are observed in response to toxic metal
exposure. These early changes may provide
further insight into mechanisms underlying
development of metal-induced diseases.
These early gene and protein responses are
also candidate biomarkers of metal expo-
sure and/or effect that could potentially be
used diagnostically in molecular and
epidemiologic studies. 
Results of the cDNA microarray experi-
ments indicate that exposure to these toxic
metals modifies expression of only a small
subset of the 1,200 total genes examined
(Figures 1 and 2), which is consistent with
the concept that these were low, relatively
nontoxic doses that did not activate large
numbers of nonspecific pathways of toxicity
response (with the exception of 50 µM
arsenic). Although there is some overlap in
the genes modified between different
metals, these data suggest that each metal
modifies expression of a largely unique set
of genes that may be characteristic of each
treatment. Although this microarray does
not contain all known metal-responsive
genes, the results show metal-specific pat-
terns of expression among the genes exam-
ined. No gene was modified by all five
chemical treatments, and only HSP-90A
was modified by all four metals. Only three
to seven genes overlapped among any two
treatments, and similarly, only a few genes
were common to any three treatments. A
similar unique pattern of gene expression
has been observed in yeast exposed to equi-
toxic doses of several different alkylating
agents (Jelinsky et al. 2000) as well as in rats
treated with different classes of drugs
(Hamadeh et al. 2002a, 2002b). Likewise,
cadmium chloride, benzo[a]pyrene and
trichloroethylene produced different pat-
terns of gene expression in the livers of
exposed mice (Bartosiewicz et al. 2001).
In this study the genes that were altered
commonly by more than one treatment
were all changed in the same direction, that
is, either increased or decreased expression.
This supports the idea that these represent
biologically relevant responses to these treat-
ments. Cadmium, chromium, and nickel
exposures all increased expression of
GLUT1 and decreased levels of transcription
activator DB1 (DB1), procollagen alpha
2(IV) subunit precursor (COL4A2), glu-
tathione peroxidase (GSHPX1), hepatoma-
derived growth factor (HDGF), and
cytochrome P450 1B1 (CYP1B1). Despite
the known ability of Cr(VI) and MMC to
cause both monoadducts and cross-links in
DNA, only 7 genes were modified in com-
mon by both of these agents. A previous
148-gene microarray experiment showed
changes in expression of 12 genes in the liver
following cadmium exposure (Bartosiewicz
et al. 2001). Organ-specific effects as well as
differences in the particular genes included
in each microarray may explain the lack of
overlap between these two studies. Previous
studies indicate that 4-hr nickel exposure
stabilizes HIF-1α protein resulting in tran-
scriptional activation of hypoxia-inducible
genes (Andrew et al. 2001; Salnikow et al.
2000). Consistent with these findings,
HIF-1α–inducible genes, including the
insulin-like growth factor binding protein
(IGFBP3) and GLUT1, were up-regulated
following nickel exposure (Figure 1) (Minet
et al. 2001). 
In addition to the metal-specific effects,
we examined the effect of arsenic dose on
gene expression. The lower-dose arsenic
exposure (5 µM) modified expression of a
wide variety of genes representing a diverse
range of protein classes such as transcrip-
tion factors, inflammatory cytokines,
kinases, and DNA repair proteins, as
shown previously in human fibroblasts (Yih
et al. 2002) and keratinocytes (Bae et al.
2002). The literature supports the observed
induction of heme oxygenase (HO1)
(Menzel et al. 1998; Taketani et al. 1989;
Yih et al. 2002) and the transcription
factor junD (junD) (Liu et al. 2001). In
addition, the immunoblot in Figure 3 con-
firmed that the HIF-1α gene expression
changes were correlated with higher pro-
tein levels. We have also demonstrated
dose-dependent increases in HIF-1α pro-
tein and mRNA levels in vascular smooth
muscle cells (data not shown), suggesting
that these effects of low-level arsenic are
not confined to a single cell type. Further
investigation will be needed to determine
the downstream consequences of increases
in levels HIF-1α and the other 11 tran-
scription factors induced in response to
5-µM arsenic exposure. Arsenic exposure
has also been associated with increased
expression of the inflammatory cytokines,
interleukin (IL)-6 and IL-8 via a mecha-
nism that may also involve MAP kinase
signaling pathways, as well as induction of
other cytokines such as IL-12B, IL-7, and
IL-2 (Wu et al. 1999). 
The decreased expression of genes
involved in DNA damage recognition and
repair support the hypothesis that arsenic
exposure may decrease the ability of
exposed cells to recognize and repair DNA
damage, potentially contributing to its car-
cinogenic and co-carcinogenic activity
(Abernathy et al. 1999; Hartwig et al. 1997;
Hartwig 1998; Rossman et al. 2001; Vogt
and Rossman 2001). For example, the fol-
lowing DNA repair genes were altered after
arsenic treatment: Xeroderma pigmentosum
group D–complementing protein (XPD,
DNA excision repair protein ERCC2),
Xeroderma pigmentosum group C–comple-
menting protein (XPC), AP endonuclease 1
(APE1), DNA ligase-1 (DNL1), DNA poly-
merase delta catalytic subunit (DPD), DNA
topoisomerase II alpha (TOP2A), DNA
damage–inducible protein GADD45 (Chen
et al. 2000; Liu et al. 2001), MCM DNA
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Arsenic (5 µM) Arsenic (50 µM) Chromium Cadmium Nickel MMC
Gene ratio ratio ratio ratio ratio ratio
abbreviationa Gene namea Up Down Up Down Up Down Up Down Up Down Up Down GenBanka
VEGF Vascular endothelial growth factor 5.86 M32977;
precursor (VEGF); vascular permeability M27281
factor (VPF)
XPC DNA-repair protein complementing XP-C 5.00 D21089
cells; xeroderma pigmentosum group C 
complementing protein (p125)
XPD Xeroderma pigmentosum group D 2.33 X52221
complementing protein (XPD); DNA 
excision repair protein ERCC2
YWHA1 14-3-3n protein eta; protein AS1; YWHAH; 2.89 1.50 L20422
YWHA1
Zyxin Zyxin + zyxin-2 2.25 3.00 X94991;
X9573
aInformation from GenBank (http://www.ncbi.nlm.nih.gov/GenBank/index.html ).
replication licensing factors 2 and 7
(MCM2, MCM7), proliferating cyclic
nuclear antigen (PCNA), O6-methylgua-
nine–DNA methyltransferase (MGMT),
replication factor C large and 40-kDa sub-
units (RFC, RFC40), and uracil–DNA gly-
cosylase precursor (UNG1). Other studies
in our laboratory using human lymphocytes
from an epidemiologic study have demon-
strated a dose-dependent correlation
between decreased expression of nucleotide
excision repair genes and chronic exposure
to arsenic in the drinking water (Andrew
et al. 2003). 
Surprisingly, increasing the dose of
arsenic to 50 µM did not simply increase
the magnitude of the change in the same set
of genes or add additional genes. Rather, we
observed a striking shift in the gene
response profile between the lower and the
higher dose. Exposure to 50 µM arsenic for
4 hr resulted in increased rather than
decreased expression of nearly all genes that
were modified, including many genes that
prepare cells to deal with adverse condi-
tions. Consistent with the concept of high-
dose arsenic acting as a heat-shock mimetic,
50 µM arsenic induced a variety of heat-
shock proteins [HSP-40, HSP-71, HSP-70
(Liu et al. 2001), HSP-60 (Liu et al. 2001),
HSP-27, HSP90A, HSP-70.1]. Many of the
other genes induced in response to higher
doses of arsenic are involved in stress
response pathways. Higher doses of arsenic
increase levels of jun kinases (JNKs), possi-
bly via mitogen-activated protein kinase
kinases, such as MAPKK3, and also activate
MAP kinases such as extracellular signal
regulated kinase (ERK3) (Cavigelli et al.
1996; Liu et al. 1996; Porter et al. 1999;
Samet et al. 1998; Wu et al. 1999).
Comparison between the microarray and
kinase assay results shown in Figure 4 indi-
cates a correlation between protein and
gene-level changes in response to arsenic
exposure for all genes that were examined in
both studies: ERK3, ribosomal S6 kinase 1
(RSK1), cAMP-dependent protein kinase
alpha-catalytic subunit (PKACα), and pro-
tein kinase B (PKB/akt1). This correlation
between gene- and protein-level changes
was also seen for PKB/akt following
chromium treatment. Further investigation
is necessary to determine how the observed
changes in kinase expression levels affect
signal transduction pathways. These experi-
ments were performed in the BEAS-2B
human bronchial epithelial cell line as well
as primary pSMC, indicating that the
observed changes are universal rather than
cell-type or cell-line specific.
This study demonstrates the feasibility
of using gene expression profiling to under-
stand toxin-induced biological responses.
Overall, the number of genes modified in
response to metal exposures was relatively
small. Although a few genes were modified
in response to more than one metal, each
metal largely altered expression of a unique
set of genes. The profile of genes induced
by high-dose arsenic exposure clearly indi-
cated a stress response, whereas the other
nonovertly toxic doses of metals led to
more subtle modification of cell signaling
pathways. Future work will focus on using
these data to explore basic mechanisms of
metal toxicity and to generate new
hypotheses. We invite other researchers to
consider our data (Table 1) from the per-
spective of their own specialized areas of
expertise. These metal response patterns
may shed new light on the mechanisms of
toxic metal–induced human diseases and
may also be useful for development of mol-
ecular biomarkers of exposure and/or effect
in mechanistic, epidemiologic, and risk
assessment studies.
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